The search was run on 27 th April 2015. We included all randomized controlled trials of any medical condition with open-label placebo and no-treatment groups. Authors independently assessed records and extracted data. We excluded nonrandomized trials and nonclinical studies. Risk of bias was assessed using Cochrane criteria. We used random-effects model for meta-analysis.
INTRODUCTION
Surveys from around the world estimate that 17% to 97% of doctors have prescribed placebos-such as dummy pills-in routine practice. 1, 2 While early estimates of placebo effects were exaggerated, 3, 4 it is widely acknowledged that placebos are able to offer some benefits to patients suffering from conditions such as pain and depression. [5] [6] [7] However, prescribing placebos is considered unethical because it has been presumed that it was necessary to deceive the patient by asserting the presence, or potential presence, of an active ingredient in order These authors contributed equally to this work.
c 2017 Chinese Cochrane Center, West China Hospital of Sichuan University and John Wiley & Sons Australia, Ltd to achieve clinical efficacy. 8, 9 Yet, several studies suggest that nondeceptive or "open-label" placebos (which are delivered to patients who are told that the treatments are placebos) are effective. This could remove the ethical objection to placebo use in clinical practice. [10] [11] [12] [13] For example, a large study of 80 participants with irritable bowel syndrome (IBS) by Kaptchuk and colleagues randomized participants to either open-label placebo pills or no-treatment controls. 11 The study demonstrated significant global improvement for IBS symptoms at both 11 and 21 days (study endpoint) among the placebo group compared to no treatment.
Despite this growing literature, a systematic review of open-label placebos has not been conducted, which makes it problematic to draw definitive conclusions about the effects of nondeceptive placebos. 14 A 2010 Cochrane Review of placebo treatments (both deceptive and open label) for all clinical conditions included some open-label placebo studies 5 but did not assess the efficacy of nondeceptive placebos alone. Furthermore, studies of nondeceptive placebos compared with a no treatment arm have since been published, 11, 15 which highlights the need for this systematic review.
The aim of this study was to assess the effect of placebos, delivered nondeceptively, compared to no treatment, for adults or children patients with any clinically diagnosed disease and for any clinical outcome.
METHODS

Eligibility criteria
Studies were eligible for this review if they included participants with any diagnosed medical condition such as pain, depression, or IBS. We (Table 1) .
We only included randomized trials. We excluded nonclinical studies, for example, those involving healthy volunteers. We did not have any age, time, or language restrictions.
Information sources and search
Searches, using the strategy listed in Appendix 1, commenced from the start date of the database through 27 th April 2015. We searched using, EMBASE Two authors independently screened all titles, abstracts, and full records for inclusion, with discrepancies resolved by discussion with a third author. Two authors extracted data independently from the included studies with discrepancies resolved by discussion or by consultation with third author. Data extraction was carried out by adapting the Cochrane Consumers and Communication Review Group Data Extraction Template (available at: http://cccrg.cochrane.org/authorresources). The following items were extracted: study design; types of participants; description of intervention and intervention components; description of comparison group; completeness of outcome data; outcome measures; country; and funding source.
Reporting outcomes
Primary outcomes, as specified by study authors, were reported (Table 1) . When not stated, the most clinically relevant outcome was selected and a rationale provided. All other outcomes for the studies are presented (Table 2). A separated table detailing instructions given to inform participants that they received a placebo is included (Table 3) .
Risk of bias in individual studies
We have assessed and reported on the methodological risk of bias of included studies in accordance with the Cochrane Handbook, 16 which recommended explicit reporting of the following individual elements for randomized control trials: random sequence generation; allocation sequence concealment; blinding (participants, personnel, and outcome assessment); completeness of outcome data, selective outcome reporting; and other sources of bias. We judged each item as being at high, low, or unclear risk of bias as set out in the criteria provided by the Cochrane Collaboration, 16 and provide a quote from the study report and a justification for our judgement for each item in the risk of bias table (Table S1 ).
Studies were deemed to be at the highest risk of bias if they scored as high or unclear risk of bias for either of the random sequence generation or allocation concealment domains, based on growing empirical evidence that these factors are particularly important potential sources of bias. 16 Two authors independently assessed the risk of bias of included studies, with any disagreements resolved by discussion to reach consensus, again involving a third author where required.
We contacted study authors for additional information about included studies, or to clarify study methods where required.
We have also reported details of the interventions and verbal instructions that accompanied the open-label placebos (Table 3) .
We commented on reporting bias qualitatively based on the characteristics of the included studies, but have not identified sufficient studies to produce a reliable funnel plot to identify and quantify publication bias.
Missing data
We contacted study authors to obtain missing and incomplete data.
Studies with missing outcome or summary data were identified, and we have reported this in the narrative description of the results.
Meta-analysis
Meta-analysis was carried out using Review Manager (RevMan) 
TA B L E 2
Summary of outcomes all outcomes with reported data
Outcome
TA B L E 3 Detailed description of interventions
Study Open-label placebo Verbal instructions (if included)
Kaptchuk et al.
11
"Placebo pills were blue and maroon gelatin capsules filled with Avicel, a common inert excipient for pharmaceuticals"
"The provider clearly explained that the placebo pill was an inactive (ie, ''inert'') substance like a sugar pill that contained no medication and then explained in an approximately 15 minute a priori script the following ''four discussion points:'' 1) the placebo effect is powerful, 2) the body can automatically respond to taking placebo pills like Pavlov's dogs who salivated when they heard a bell, 3) a positive attitude helps but is not necessary, and 4) taking the pills faithfully is critical."
Kelley et al. 15 "Blue capsules containing microcrystalline cellulose." "Patients were instructed to take two placebo pills, twice daily."
Sandler Carvalho et al. 23 "A typical prescribed medicine bottle of placebo pills with a label clearly marked "placebo pills" and "take 2 pills twice a day." The placebo pills were Swedish Orange gelatin capsules filled with microcrystalline cellulose, a common inert excipient for pharmaceuticals" "The PI explained that the placebo pill was an inactive substance, like a flour pill, that contained no active medication in it. After informed consent, all participants were asked if they had heard of the "placebo effect" and explained in an approximately 15-minute a priori script, adopted from an earlier open label placebo study, 18 the following "4 discussion points": (1) the placebo effect can be powerful, (2) the body automatically can respond to taking placebo pills like Pavlov dogs who salivated when they heard a bell, (3) a positive attitude can be helpful but is not necessary, and (4) taking the pills faithfully for the 21 days is critical. All participants were also shown a video clip (1 minute and 25 seconds) of a television news report, in which participants in an OLP trial of irritable bowel syndrome were interviewed (excerpted from: http://www.nbcnews. com/video/nightly-news/40787382#40787382)" Schaefer et al.
22
"The placebo group received a white tube containing 28 placebo pills. The tube was labeled with the logo of the local university and the following information: 'placebo pills (28) , take one in the morning and one before night for 14 days' ."
"We explained that placebos are inactive substances and that they contain no medications. Participants were further told that although placebos contain no medication, placebo effects may still be powerful. The effect was explained to them by pointing out that the body may automatically respond to taking placebo pills, like Pavlov's dogs that salivated when they heard the bell. In addition, they were told that a positive attitude may be helpful for the placebo effect, but is not necessary. Last, they were told that those participants who were in the placebo group needed to take the placebos faithfully." measures were identified. The standardized mean difference (SMD), standard deviation (SD), and 95% confidence interval (CI) were calculated.
We anticipated heterogeneity in terms of intervention modalities, conditions, outcome measures, patients, and effect sizes. For this reason, a random effects model was used for the meta-analysis.
The degree of heterogeneity was assessed by visual inspection of forest plots and using the chi-square test for heterogeneity.
Heterogeneity was further quantified by using the I 2 statistic. We considered an I 2 value of 50% or more as representing a substantial level of heterogeneity. 16 
Protocol amendments
There was an insufficient number of trials included to conduct the planned subgroup analyses.
We deviated from the protocol by including only clinical studies for three reasons. First, the clinical and nonclinical studies were qualitatively different, undermining the rationale for inclusion within the same systematic review. The latter mostly investigated the effects of decaffeinated coffee on healthy volunteers. [17] [18] [19] [20] The protocol was also amended such that "no additional treatment" control groups were considered equivalent to "no treatment" controls. 21, 22 This was justified as it may be unethical to withhold known beneficial treatment in a trial where the only intervention is a placebo. The effect of open-label placebos can still be fairly assessed so long as the addition of placebo is the only difference between the control and intervention groups. Furthermore, identifying a strict "no treatment" group is particularly difficult in a clinical trial, where enrolling and observing participants may result in the welldocumented Hawthorne effects and hence could be considered an intervention themselves (explored in further in the discussion). Worthy of note is that this definition of a "no treatment" control group is consistent with the 2010 Cochrane Review that examined placebos against no treatment. 5
Results
After removing duplicates we screened 348 trials, assessed 24 articles for eligibility, and identified five trials (260 patients) that met our inclusion criteria (Figure 1) . 11, 13, 15, 22, 23 The risk of bias for each study and domain is shown in Figure 2 . Given that we are specifically assessing only open-label studies, bias for participant blinding of is necessarily high. Thus, excluding the high risk of participant blinding, overall low risk of bias was assessed in 47% of domains, with 33% at unclear risk and 20% at high risk. We suggest that overall, this implies that there is a moderate risk of bias from all studies. All of these were eligible for meta-analysis ( Figure 3 ). We found a positive effect of nondeceptive placebos SMD) 0.88, 95% CI 0.62 to 1.14, P < 0.00001, I 2 = 1%).
The conditions treated in these trials were: depression, 15 attention deficit hyperactivity disorder (ADHD), 13 IBS, 11 allergic rhinitis, 22 and chronic lower back pain. 23 One study reported harms, 13 and found a nonsignificant reduction in side effects within the open-label placebo group compared with the treatment and control groups.
Narrative summary of results
Kaptchuk et al. 11 This parallel two-group trial randomized 80 patients
to receive either open-label placebo pills presented as in Table 1 or no treatment. Investigators then measured the effect of the treatment on the IBS Global Improvement Scale (IBS-GIS, stated primary outcome). Open-label placebo produced significantly higher mean global improvement scores (IBS-GIS) at both 11-day midpoint and at 21-day endpoint ( Table 2) . 15 This pilot two-group parallel trial randomized 20 patients diagnosed with nonpsychotic major depressive disorder (MDD) to either open-label placebo (2 pills/day) or waitlist control. At baseline and after two weeks investigators used the 17-item Table 2) .
Kelley et al.
Carvalho et al. 23 This two-group parallel trial of 83 patients with at least three months of chronic lower back pain. Participants were randomized to receive two placebo tablets, taken twice daily, or treatment as usual, for three weeks. All participants were again primed toward placebo for 10 to 15 minutes at the midpoint review. Primary outcomes were mean weekly retrospective pain assessments (0 to 10) and the Roland-Morris Disability Questionnaire (RMDQ) assessed at three weeks; we took RMDQ to be the most relevant clinical outcome for the meta-analysis ( Table 1 ). The open-label placebo demonstrated a statistically significant benefit over treatment as usual (Table 2) Schaefer et al. 22 (Table 2) .
Risk of bias
As shown in Figure 2 , overall, the studies had a moderate risk of bias.
Participants in the studies were, by definition, unblinded, and two of the studies used unblinded outcome assessors. 15 None of the studies were at a high risk of bias for incomplete outcome reporting or selective reporting. Three of the studies were at an unclear risk of bias for incomplete outcome data. 11, 15, 23 Two of the studies was at a high risk of "other" bias. These were because data in Sandler et al., were not presented for the teacher-reported outcome measure, although this was commented on in the text, 13 and Schaefer et al., had a trend toward higher symptom severity within the placebo-treated group, and did not describe participants at baseline with respect to their allergic triggers (see Table S1 ).
Screening Eligibility
Records screened (n = 348)
Records excluded (n=324)
Full-text arƟcles assessed for eligibility 
Included
Records idenƟfied through database searching
IdenƟficaƟon
AddiƟonal records idenƟfied through other sources (n = 4)
Records aŌer duplicates and animal studies removed (n = 348) F I G U R E 1 PRISMA flowchart for studies selection
DISCUSSION
Summary of evidence
We found that open-label placebos have a statistically significant, medium-sized effect across the five randomized trials that were included. To our knowledge, this is the first systematic review to evaluate the effect of open-label placebos. However, the results of this meta-analysis should be interpreted with caution because of the small number of studies, the small sample sizes of the included studies, the moderate risk of bias identified and the heterogeneity of sample populations (children and adults), clinical conditions, and reporting methods.
Comparison with existing evidence
Systematic reviews of placebos in general show a small but statistically significant benefit of placebos. 5, 24 The effect size estimate for open-label placebos in the current systematic review and metaanalysis is larger than previous estimates for deceptively delivered placebos, 5 suggesting the possibility that open-label placebos may have effects that are equal to, or perhaps even larger than, , or it could be that the effects of "standard" placebos are an underestimate because they are delivered in conditions of doubt. 25 However, the evidence for the efficacy of placebos delivered in blinded conditions is much more robust. Moreover, given that conscious expectancy is presumably less powerful when placebos are delivered openly, it is often suggested that open-label placebos are likely to be less effective than placebos delivered deceptively. Despite this, we are aware of only four studies that compare the physiological outcomes of open-label and deceptively delivered placebos, [17] [18] [19] [20] and none reported a significant difference between the open-label placebos.
Strengths and weaknesses
To our knowledge, this is the first systematic review and meta-analysis of open-label placebos. It provides evidence to suggest that openlabel placebos provide symptom relief to patients suffering from IBS, depression, allergic rhinitis, chronic lower back pain, and ADHD. The key limitation was size: there were five studies (260 patients) eligible for inclusion. This made it difficult to assess the risk of publication bias.
Two of the five included studies were carried out by the same author, suggesting the need for independent replication within this field.
Furthermore, four in five of the studies included interventions with explicit positive suggestions alongside the open-label placebo, 11, 13, 22, 23 making the effects of nondeceptive placebos difficult to distinguish from benefits of positive framing. 26 The only study lacked any positive framing and instruction sets 15 A limitation of our methodology is that in some cases, the authors had to judge the most clinically relevant outcome of a study, we address this by providing a rationale in Table 1 and have reported on all outcomes separately (Table 2) . Finally, while statistical heterogeneity was low due to the consistently positive effect, the studies varied in terms of participants (children/adults), conditions (IBS, depression, allergic rhinitis, back pain, and ADHD), control interventions (no treatment versus waiting list versus treatment as usual), and outcome measures. The quality of the placebos and fidelity of the consultations in which the open-label placebos were delivered is also another potential source of bias that we could not assess due to lack of reporting.
How open-label placebos might work
The mechanisms by which open-label placebos remain to be confirmed, with classical conditioning being the most strongly supported by F I G U R E 3 Forest plot for main outcome evidence. 30 A recent clinical study of open-label placebos showed that prolonged conditioning (four versus one day) demonstrated greater benefit in the treatment of pain. 31 This dose-response data are evidence of causation. 32 In addition, conscious expectancy is a relevant mechanism here, as we have shown that open-label placebos are often accompanied by a suggestion that the placebo is effective. It is known that the expectation of pain relief has been found to modulate the central regulation of pain through, in particular, the dopamine reward system and the endogenous opioid system. 30 There is also a growing body of evidence that in addition to what practitioners say, the way in which they deliver these messages (for example, with more or less empathy) can also affect health outcomes. [33] [34] [35] "Embodied cognition" is a relatively new theory that beginning to
help explain how open-label placebos might work but is currently at the speculative stage. According to this theory, 36 our physical interaction with the world influences or even determines our cognitions. 37 For example, the sound of the dentist's drill might trigger a specific bodily sensation. 38 Hence, sensory signals could evoke different reactions including those involved in positive and negative healing experiences. 38, 39 Embodied cognition is related to conditioning because it operates at a subconscious level and is automatic. However, it also differs in important respects. In the real-world setting of health care, these putative placebo mechanisms are likely to operate in unison. Therefore, it is reasonable to assume that these proposed mechanisms are combined, to differing degrees depending on the individual and their disease, to demonstrate efficacy.
Conclusions and implications
Open-label placebos may have a medium-sized effect that may help reduce symptoms in patients with some medical conditions. Since placebos may not require deception, this study also suggests that ethical restrictions to using placebos in clinical practice need to be revisited, 40 
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